Replies to post #141267 on Biotech Values

[genisi]

"JNJ has completed the acquisition of CorImmun GmbH, a privately held drug development company in Germany, for an undisclosed upfront payment and a contingent future clinical milestone payment.
CorImmun's lead compound, COR-1, is a small cyclic peptide currently in early clinical development for the treatment of heart failure."

http://www.prnewswire.com/news-releases/janssen-acquires-corimmun-160660595.html